The venture — called BlueRock Therapeutics — represents the largest Series A financing for a biotech company to date. Cardiovascular diseases and neurodegenerative disorders will be the initial projects of BlueRock, which will have operations in Toronto, New York and Boston.
“We have closely tracked the field of regenerative medicine for the past five years and believe the time is right to invest in stem cell therapies given recent breakthroughs in cell differentiation, manufacturing and engineering,” Jerel Davis, PhD, managing director at Versant Ventures, said in a prepared statement.
More articles on transactions and valuations:
22 recent hospital transactions and partnerships
Trinitas Regional Medical Center, St. Joseph’s launch integrated behavioral network
University of Michigan Health System files LOIs to acquire Metro Health
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
